Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Evaluation of quality of life (QOL) in asthma patients during 6 months formoterol therapy Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001
Improvement in HRQoL of COPD patients after 9 months‘ treatment with tiotropium bromide: use of a new scale for daily medical practice Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Training patients on how to use metered dose inhaler (MDI) by using the 2Tone will improve asthma quality of life (AQOL) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 46s Year: 2001
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Budesonide/formoterol adjustable maintenance dosing (AMD) improves health-related quality of life (HRQL) compared with high-dose budesonide (AMD) Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Impact of asthmatic patient satisfaction with the inhaler upon adherence, disease control and quality of life. Results of the ASCONA study Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis Source: Annual Congress 2004 - Bronchiectasis Year: 2004
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Quality of life and symptoms improvement after 6 months treatment with roflumilast 500 μg daily in a large Greek COPD cohort Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013
Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003